Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2014) 3 PP309 | DOI: 10.1530/boneabs.3.PP309

Osteoporosis: treatment

Treatment of severe vertebral osteoporosis with teriparatide or 1--84-PTH: results from a Danish Database Initiative

Lars Hyldstrup1, Bente L Langdahl2, Pia Eiken3, Pernille Hermann4, Peter Schwarz5, Marianne Kleis Moeller6, Finn Bennedbaek7, Ole Rintek Madsen8, Bo Abrahamsen8, Lis Stilgren9, Anita Smitz10, Randi Pelch11, Helle Brockstedt12, Anne Jarløv13, Marianne Mørch14, Henrik Ancher Sorensen15, Lene Mortensen16, Per Nygaard Andreasen17, Hans Christian Hoeck18 & Jens-Erik Beck Jensen1


1Hvidovre Hospital, Hvidovre, Denmark; 2Aarhus Universitetshospital, THG, Aarhus, Denmark; 3Nordsjaellands Hospital, Hilleroed, Denmark; 4Odense University Hospital, Odense, Denmark; 5Glostrup Hospital, Glostrup, Denmark; 6Regionshospitalet Horsens, Horsens, Denmark; 7Herlev Hospital, Herlev, Denmark; 8Gentofte Hospital, Gentofte, Denmark; 9Svendborg Sygehus, Svendborg, Denmark; 10Vejle Sygehus, Vejle, Denmark; 11Holbaek Sygehus, Holbaek, Denmark; 12Silkeborg Sygehus, Silkeborg, Denmark; 13Frederiksberg Hospital, Frederiksberg, Denmark; 14Aarhus Universitetshospital, PGO, Aarhus, Denmark; 15Amager Hospital, København, Denmark; 16Regionshospitalet Viborg, Viborg, Denmark; 17Gigthospitalet Graasten, Graasten, Denmark; 18Speciallægeklinikken, Aalborg, Denmark.

A Danish database initiative was established in 2003 with the purpose of evaluating patients treated with teriparatide. After the introduction in 2006 of 1–84-PTH, these patients were also included. A total of 1494 patients from 19 centers were reported to the database, until closure in 2011. The reported patients correspond to a third of all patients in Denmark receiving anabolic treatment during this time period. With regard to age and sex the reported patients do not differ from the entire group of patients treated with teriparatide or 1–84-PTH. Almost 80 patients. of patients treated were having at least two vertebral fractures, while the remaining group had a single vertebral fracture in combination with a T-score <−3.0. Thirty-five patients. of the patients were reported to be treatment naïve, while 38% had suffered a vertebral fracture despite antiresorptive treatment. This pattern did not change over time.

Eighty-three patients. were treated with teriparatide, while 17 patients. received 1–84-PTH. The vast majority was treated for 18 months, since this was the maximum reimbursement period for the main part of the study. Comparing teriparatide and 1–84-PTH parallel patterns in changes in BMD of the spine and total hip were seen, with ~10 patients. increase at the lumbar spine and one patient. increase at the total hip. Identical responses were found in females and males, as well as in patients previously treated with bisphosphonates compared to treatment naïve. Side effects reported were few and equally distributed between the two treatments, except for hypercalcaemia that was more frequently reported in patients treated with 1–84-PTH. Only very few patients stopped treatment prematurely due to side effects.

With the use of voluntary clinical database additional information on how a new treatment is adopted by clinicians and how patients respond to treatment.